Biomarker-guided medication strategies compared with antidepressant treatment alone
About this title
Read the official source — NCT06054321Understand this study
Who could participate?
Listed age limits: 19 years to 65 years.
What will I do during this study?
Your assigned group receives either escitalopram alone or a stepwise medication strategy that can involve adding another medication. The protocol calls for treatment decisions or dose increases to be reviewed every three weeks.
- Listed locations
- GwangjuSee all locations and recruitment
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Chonnam National University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Locations
- South Korea
- Age range
- From 19 Years to 65 Years
- Official registry ID
- NCT06054321
- Official title
Show the full official title
A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients
Recruitment & locations
Gwangju
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Chonnam National University Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including stepwise pharmacotherapy and antidepressant monotherapy group.
Who can participate?
Listed age limits: 19 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
